ArticleBMC microbiology2025
Dissemination of KPC-2-producing carbapenem-resistant Klebsiella pneumoniae ST656 in Eastern China.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Temporal Trends in Antimicrobial Resistance in a Tertiary Hospital in Western Guangxi, China: A Five-Year Surveillance Study (2021-2025).Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Carbapenem-resistant Klebsiella pneumoniae (CRKP), particularly strains producing Klebsiella pneumoniae carbapenemase (KPC), pose a severe global health challenge due to limited therapeutic options and high mortality. While ST11 is the predominant KPC-producing lineage in China, the clinical and epidemiological significance of ST656 remains largely unexplored. We conducted a genomic and epidemiological investigation of twenty-five KPC-2-producing K. pneumoniae ST656 isolates collected from patients with severe pulmonary comorbidities in a tertiary hospital in Eastern China between July 2020 and October 2021. Antimicrobial susceptibility testing, whole-genome sequencing (WGS), phylogenetic analysis, plasmid profiling and conjugation assays were performed to determine resistance mechanisms, clonal relationships and plasmid transferability. Clinical information showed all 25 isolates originated from distinct patients in a tertiary hospital in Eastern China, predominantly older male post-lung transplantation cases with severe pulmonary disease, from intensive care units and thoracic surgery wards. All isolates displayed highly similar multidrug-resistant profiles, being resistant to most β-lactams, levofloxacin and trimethoprim-sulfamethoxazole, with limited susceptibility to amikacin and tigecycline. Genomic characterization of representative strain CRE132 showed that blaKPC−2 was located on a conjugative IncFII plasmid, and that this plasmid could transfer carbapenem resistance to Escherichia coli in conjugation assays. ST656 isolates in our study exhibited modest increase in virulence-associated traits, growth rates and certain adaptability compared with ST11 isolates. This study represents the first genomic and epidemiological investigation demonstrating nosocomial clonal dissemination of KPC-2–producing K. pneumoniae ST656 in China. These findings highlight the importance of continued genomic surveillance and improved understanding of this emerging lineage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.